This is a preview of subscription content, log in via an institution to check access.
Reference
Christensen H, et al. Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact. Vaccine : 5 Apr 2013. Available from: URL: http://dx.doi.org/10.1016/j.vaccine.2013.03.034
Additional information
* The cost-effectiveness analysis was from an NHS perspective.
** 3.5% over the first 30 years, 3.0% over years 31-75, and 2.5% over years 76-99
Rights and permissions
About this article
Cite this article
Meningococcal B vax potentially cost effective in the UK. PharmacoEcon Outcomes News 677, 3 (2013). https://doi.org/10.1007/s40274-013-0344-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0344-3